In the first detailed glimpse of palbociclib’s impact on overall survival–a key feature to the future prospects of this flagship program–the therapy has failed to demonstrate a statistically significant improvement in extending patients’ lives after an initial assessment.

…read more

Source: Pfizer’s flagship palbociclib stymies cancer progression but falls short on survival


0 No comments